化疗后当天与次日使用培非格司亭的真实世界中性粒细胞减少性发热率。
Real-world febrile neutropenia rates with same-day versus next-day pegfilgrastim after myelosuppressive chemotherapy.
机构信息
Clinical Services Department, Utah Cancer Specialists, Salt Lake City, UT 84124, USA.
Biostatistics Department, EMB Statistical Solutions, LLC, Overland Park, KS 66210, USA.
出版信息
Future Oncol. 2022 Jul;18(23):2551-2560. doi: 10.2217/fon-2022-0365. Epub 2022 Jun 16.
To compare the incidence of febrile neutropenia (FN) after same-day versus next-day pegfilgrastim. This single-institution, real-world, retrospective electronic health record-based study included patients who received chemotherapy and prophylactic same-day or next-day pegfilgrastim/pegfilgrastim-cbqv. In cycle 1, 117 patients received same-day pegfilgrastim and 180 patients received next-day pegfilgrastim. FN episodes in cycle 1 occurred in 6.0 versus 6.7% of patients with same-day versus next-day pegfilgrastim, respectively (p = 0.814). Across all cycles, 8.5 and 9.4% of patients experienced ≥1 FN episode after same-day versus next-day pegfilgrastim, respectively (p = 0.793). In the breast cancer patient subgroup, FN occurred 3.2% of same-day pegfilgrastim cycles versus 1.8% of next-day pegfilgrastim cycles (p = 0.938). No significant differences were detected between same-day and next-day pegfilgrastim administration.
比较同日与次日使用培非格司亭的发热性中性粒细胞减少症（FN）发生率。这是一项单机构、真实世界、回顾性的基于电子病历的研究，纳入了接受化疗和预防性同日或次日培非格司亭/培非格司亭-cbqv的患者。在第 1 周期中，117 例患者接受同日培非格司亭，180 例患者接受次日培非格司亭。第 1 周期中，同日培非格司亭组和次日培非格司亭组分别有 6.0%和 6.7%的患者发生 FN 事件（p=0.814）。在所有周期中，同日培非格司亭组和次日培非格司亭组分别有 8.5%和 9.4%的患者发生≥1 次 FN 事件（p=0.793）。在乳腺癌患者亚组中，同日培非格司亭组和次日培非格司亭组的 FN 发生率分别为 3.2%和 1.8%（p=0.938）。同日和次日使用培非格司亭没有发现显著差异。
Zotero 插件